

August 31, 2025

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

BSE Scrip Code: 506943

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Ref: Change in Director – Cessation of Non-Executive Independent Director upon completion of term

This is to inform you that Ms. Padmini Khare Kaicker (DIN: 00296388), Non-Executive Independent Director of the Company, has completed the term of five years as an Independent Director of the Company on August 30, 2025 and thus, has ceased to be Director of the Company.

Details as required under Regulation 30 of the Listing Regulations and the SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, as amended from time to time are given below.

Sr.	Disclosure requirement	Details
No.		
1	Reason for change viz. appointment, re appointment,	Cessation upon
	resignation, removal, death or otherwise	completion of term of



		five years as an Independent Director.
2	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment	August 30, 2025 (end of day)
3	Brief profile	Not Applicable
4	Disclosure of relationships between directors	Not Applicable

We request you to take the above disclosure on record.

Thanking you,

Yours faithfully,

For J. B. Chemicals & Pharmaceuticals Limited

Sandeep Phadnis
Vice President – Secretarial
& Company Secretary